Rapid Response - COVID-19 Rapid Screening Test [Box of 25]

  • $348.75
    Unit price through 
Shipping fees calculated at the payment stage.

Please note, all deliveries can be made from Friday January 14, 2021.

The Rapid Response ™ Antigen Testing Device is the perfect screening tool for organizations looking to try and protect their workplace from the risk of containment from COVID-19.

Used as part of a comprehensive rapid testing program for COVID-19, the BTNX nasal device offers rapid, easy-to-use and reliable testing. Testing all staff 1-2 times per week will help detect the virus early and reduce the likelihood of COVID-19 spreading.

COVID-19 Rapid Response Antigen Rapid Test Device. It is an efficient, precise and reliable test method that can be used by any healthcare professional. It is easy to use and gives results in 15 minutes!

The BTNX Rapid Response ™ COVID-19 Rapid Antigen Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal secretion samples.


The COVID-19 Rapid Response ™ Rapid Antigen Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of viral SARS-CoV-2 nucleoprotein antigens from nasal and nasopharyngeal secretions of individuals suspected of COVID -19 within 6 days of onset of symptoms. This test is authorized for use at the Point of
Care, that is, in patient care settings.

The results relate to the identification of the viral nucleoprotein antigen of SARS-CoV-2. Antigens are usually detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with the patient's history and other diagnostic information is necessary to determine the state of infection.

Positive results do not exclude bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of the disease. Laboratories are required to report all positive results to the appropriate public health authorities.

Negative results should be treated as presumptions and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including control decisions. infections. Negative results should be considered in the context of the patient's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed by molecular testing, if necessary, for the patient.

The Rapid Response ™ COVID-19 Antigen Rapid Test Device is intended for use by qualified laboratory personnel or healthcare professionals.

By purchasing this product, you agree to follow the manufacturer's intended use and conditions of sale of this website.

0.05 lbs
Technology Antigen
Sensitivity 78.6% - 96.2%
Specificity 96.5% - 100%
The duration of the conversation 6-18 months
Storage temperature 2-30°C/36-86°F
Result time 15 minutes
Sampling technique Shallow nasal

We also recommend you